Answers are grounded in this paper and cite their sources.
Precision oncology approaches have accelerated recently due to advancements in our ability to detect oncogenic mutations in tumor samples. Oncogenic alterations, most commonly gene fusions, have now been detected for the genes encoding the TRKA, TRKB, and TRKC receptor tyrosine kinases across multiple tumor types. The scientific rationale for the targeting of the TRK oncogene family will be discussed here.
No takes yet. Share an insight, caveat, or question.
Vaishnavi et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: